Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nektar Builds Case For Irinotecan-Inspired NKTR-102 In Cancer

Executive Summary

Company’s R&D day stresses areas of unmet need for NKTR-102 in metastatic breast cancer. Company also highlights data from a Phase II study showing the drug’s promise in high-grade brain cancer.

You may also be interested in...



Nektar Branches Out In Pain, Hails Next Generation Of Analgesics

At R&D event, company signals shift of Phase III for lead pain drug NKTR-181 to mid-2014 from earlier in the year. Nektar also featured crop of new drugs targeted at different molecular pathways, including NKTR-192, a partial agonist for acute pain, and a new kind of sodium channel blocker called NKTR-171 for neuropathy.

Nektar Branches Out In Pain, Hails Next Generation Of Analgesics

At R&D event, company signals shift of Phase III for lead pain drug NKTR-181 to mid-2014 from earlier in the year. Nektar also featured crop of new drugs targeted at different molecular pathways, including NKTR-192, a partial agonist for acute pain, and a new kind of sodium channel blocker called NKTR-171 for neuropathy.

Nektar Readies Phase III Breast Cancer Trial Of NKTR-102, On Its Own

Nektar Therapeutics Inc. will launch the Phase III BEACON trial by the end of this year for its NKTR-102, a next-generation version of the now generic topoisomerase 1 inhibitor irinotecan (Pfizer Inc.’s Camptosar). The trial, in pretreated metastatic breast cancer patients, will have a raft of endpoints designed to help gain acceptance in the crowded field.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS055671

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel